



SZABO SCANDIC

Part of Europa Biosite

Produktinformation



Forschungsprodukte & Biochemikalien



Zellkultur & Verbrauchsmaterial



Diagnostik & molekulare Diagnostik



Laborgeräte & Service

Weitere Information auf den folgenden Seiten!
See the following pages for more information!



Lieferung & Zahlungsart

siehe unsere [Liefer- und Versandbedingungen](#)

Zuschläge

- Mindermengenzuschlag
- Trockeneiszuschlag
- Gefahrgutzuschlag
- Expressversand

SZABO-SCANDIC HandelsgmbH

Quellenstraße 110, A-1100 Wien

T. +43(0)1 489 3961-0

F. +43(0)1 489 3961-7

mail@szabo-scandic.com

www.szabo-scandic.com


[linkedin.com/company/szaboscandic](https://www.linkedin.com/company/szaboscandic) 

PRODUCT INFORMATION



6 β -Naltrexol-d₃ Item No. 18350

CAS Registry No.: 1435727-11-9
Formal Name: (5 α ,6 β)-17-(cyclopropylmethyl)-4,5-epoxy-d₃-morphinan-3,6,14-triol
Synonym: 6 β -hydroxy Naltrexone-d₃
MF: C₂₀H₂₂D₃NO₄
FW: 346.4
Purity: \geq 98%
Supplied as: A neat solid
Storage: -20°C
Stability: \geq 5 years



Information represents the product specifications. Batch specific analytical results are provided on each certificate of analysis.

Description

6 β -Naltrexol-d₃ (Item No. 18350) is intended for use as an internal standard for the quantification of 6 β -naltrexol (Item No. 15896) by GC- or LC-MS. The accuracy of the sample weight in this vial is between 5% over and 2% under the amount shown on the vial. If better precision is required, the deuterated standard should be quantitated against a more precisely weighed unlabeled standard by constructing a standard curve of peak intensity ratios (deuterated versus unlabeled).

6 β -Naltrexol is the major metabolite of naltrexone (Item Nos. ISO60192 | 15520).¹ It is a neutral μ -opioid receptor antagonist (K_i = 94 pM).^{2,3} This product is intended for research and forensic applications.

This product is qualified as a Reference Material that has been manufactured and tested to ISO/IEC 17025 and ISO 17034 international standards.

References

1. Porter, S. J., Somogyi, A. A., and White, J. M. Kinetics and inhibition of the formation of 6 β -naltrexol from naltrexone in human liver cytosol. *Br. J. Clin. Pharmacol.* **50**(5), 465-471 (2000).
2. Wang, D., Raehal, K. M., Bilsky, E. J., *et al.* Inverse agonists and neutral antagonists at μ opioid receptor (MOR): Possible role of basal receptor signaling in narcotic dependence. *J. Neurochem.* **77**(6), 1590-1600 (2007).
3. Porter, S. J., Somogyi, A. A., and White, J. M. *In vivo* and *in vitro* potency studies of 6 β -naltrexol, the major human metabolite of naltrexone. *Addict. Biol.* **7**(2), 219-225 (2002).

WARNING

THIS PRODUCT IS FOR RESEARCH ONLY - NOT FOR HUMAN OR VETERINARY DIAGNOSTIC OR THERAPEUTIC USE.

SAFETY DATA

This material should be considered hazardous until further information becomes available. Do not ingest, inhale, get in eyes, on skin, or on clothing. Wash thoroughly after handling. Before use, the user must review the [complete](#) Safety Data Sheet, which has been sent via email to your institution.

WARRANTY AND LIMITATION OF REMEDY

Buyer agrees to purchase the material subject to Cayman's Terms and Conditions. Complete Terms and Conditions including Warranty and Limitation of Liability information can be found on our website.

Copyright Cayman Chemical Company, 07/31/2019

CAYMAN CHEMICAL

1180 EAST ELLSWORTH RD
ANN ARBOR, MI 48108 · USA

PHONE: [800] 364-9897
[734] 971-3335

FAX: [734] 971-3640

CUSTSERV@CAYMANCHEM.COM
WWW.CAYMANCHEM.COM